Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02509975
Other study ID # OCL503-P2-PAE-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2015
Est. completion date May 2018

Study information

Verified date August 2018
Source IMBiotechnologies Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, pilot, open-label, uncontrolled, non-randomized safety and effectiveness study of OCL 503 in men with BPH.


Description:

Prior to entering the study, all patients will undergo pre-study assessments including compliance with inclusion and exclusion criteria, laboratory assessments, IPSS, uroflowmetry, IIEF, and MRI pelvic imaging. Following conventional catheter angiography with cone-beam CT to confirm catheter placement and prostatic vasculature, each patient will undergo transarterial embolization with OCL 503. OCL 503 will be administered intra-arterially via microcatheter until there is stasis of blood flow.

Patient assessments include blood work, IPSS, uroflowmetry, IIEF, MRI and patient interviews conducted at 3 months, 6 months, and 12 months post embolization.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date May 2018
Est. primary completion date May 2018
Accepts healthy volunteers No
Gender Male
Age group 51 Years and older
Eligibility Inclusion Criteria:

- Patient has received a diagnosis of BPH with moderate to severe LUTS, as determined by IPSS

- Patient is greater than 50 years of age

- Patient has had a pelvic examination within the past 6 months

- Patient has been refractory to medical therapy for the last 6 months, or has refused medical therapy

- Patient has a Qmax below 15 mL/s or acute urinary retention

- Prostate is larger than 40 cubic centimetres

- Patient is willing and able to provide written, informed consent

Exclusion Criteria:

- Known malignancy

- Serum PSA > 10 ng/mL at screening

- Advanced atherosclerosis and tortuosity of the iliac arteries

- Prior transurethral resection of the prostate (TURP)

- Post void retention (PVR) > 250 mL

- Chronic use of metronidizole

- Phytotherapy for BPH within last two weeks of screening visit

- Secondary renal insufficiency due to prostatic obstruction

- Chronic renal failure (GSR < 60)

- Large bladder diverticula or bladder stones

- Claustrophobia or other contraindications related to performing MRI

- Compromised hematopoietic function

- Anaphylactic reaction to drug or anesthetic, allergic reaction to iodine or contrast media

- Investigational drug or experimental therapy in the past 4 weeks

- Abnormal coagulation profile

- Allergy to bovine collagen

Study Design


Intervention

Device:
Prostate artery embolization.
Embolization of the prostatic vasculature with OCL 503 using a microcatheter.

Locations

Country Name City State
Canada University of Alberta Hospital Edmonton Alberta

Sponsors (1)

Lead Sponsor Collaborator
IMBiotechnologies Ltd.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of OCL 503 as measured by Adverse Events reporting. Measurement of device related adverse events post embolization of the prostatic vasculature, at 30 days. 12 months
Primary International Prostate Symptom Score (IPSS) Measurement of IPSS at 12 months post embolization of the prostatic vasculature with OCL 503. 12 months
Secondary Tissue Response Measurement in the change in size of the prostate by MRI at 12 months post embolization of the prostatic vasculature with OCL 503. 12 months
Secondary Uroflowmetry Measurement of Qmax, post-voiding bladder retention (PVR) at 12 months post embolization of the prostatic vasculature with OCL 503. 12 months
Secondary International Index of Erectile Function (IIEF) Measurement of IIEF by questionnaire at 12 months post embolization of the prostatic vasculature using OCL 503. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04807296 - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP) N/A
Recruiting NCT05574244 - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT04245566 - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH Phase 3
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Completed NCT03246880 - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Phase 3
Completed NCT02206243 - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed NCT02283684 - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Phase 4
Completed NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) Phase 1/Phase 2
Completed NCT01438775 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT01139762 - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Phase 3
Completed NCT01152190 - A Study in Benign Prostatic Hyperplasia Phase 3
Active, not recruiting NCT00400894 - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma N/A
Completed NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Phase 3
Unknown status NCT00381108 - Study of the Effects of Pomegranate Tablets on Enlarged Prostates Phase 1
Completed NCT00701779 - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Phase 4
Terminated NCT02962674 - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH. N/A
Active, not recruiting NCT05415748 - Deprescribing Tamsulosin in Older Men Phase 4
Recruiting NCT04853914 - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound. N/A
Completed NCT04831476 - Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)